Certara provides scientists with automated, comprehensive tools for PK/PD analysis and modeling, and announces industry’s first PK/PD certification program for Phoenix software in partnership with ...

Bioavailability of the hedgehog pathway inhibitor GDC-0449 in a phase I pharmacokinetic (PK) study in healthy female subjects. Background: Serdemetan is a compound that can cause replicative stress ...

PRINCETON, NJ--(BUSINESS WIRE)--Certara®, the global model-informed drug development and decision support leader, today announced the launch of Phoenix® 8.2, the ...

Certara, the global model-informed drug development and decision support leader, announced the launch of Phoenix 8.2, the industry gold standard in pharmacokinetic/ pharmacodynamic (PK/PD) modelling ...

Certara, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, announced the launch of Phoenix 8.1. Phoenix is the most advanced and ...

Combined therapy of EGFR TKI and VEGFR TKI may produce a greater therapeutic benefit and overcome EGFR TKI-induced resistance. However, a previous study shows that a combination of EGFR TKI erlotinib ...

PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global leader in model-informed drug development, regulatory science, market access and real-world evidence services, today announced the launch of ...